gsk3003891a
Vaccineexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 22, 2013 (NCT01905215)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk3003891a
- gsk3003892a
- gsk3003893a
- gsk3003895a
- gsk3003896a
- gsk3003898a
- gsk3003899a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03191383 | Phase 2 | Jul 3, 2017 | GlaxoSmithKline |
| NCT02956837 | Phase 2 | Nov 10, 2016 | GlaxoSmithKline |
| NCT02753413 | Phase 2 | Apr 1, 2016 | GlaxoSmithKline |
| NCT02360475 | Phase 2 | Mar 1, 2015 | GlaxoSmithKline |
| NCT01905215 | Phase 1 | Jul 22, 2013 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2013 |
1 organizations
Page 1 / 1